Comparative Pharmacology
Head-to-head clinical analysis: NEXTERONE versus SORINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXTERONE versus SORINE.
NEXTERONE vs SORINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class III antiarrhythmic agent; prolongs cardiac action potential duration by blocking potassium channels (IKr), primarily affecting the atria and ventricles.
Selective beta-1 adrenergic receptor antagonist; decreases cardiac output, heart rate, and blood pressure.
Intravenous loading: 150 mg over 10 minutes, then 1 mg/min for 6 hours, followed by maintenance infusion of 0.5 mg/min. Oral: 400 mg twice daily for loading (total 1200 mg/day) for 7-10 days, then maintenance 200-400 mg once daily.
5 mg orally once daily, increased after 4 weeks to 10 mg orally once daily if tolerated and needed.
None Documented
None Documented
Terminal elimination half-life of 58 days (range 25-110 days) due to extensive tissue distribution and slow release from lipid stores. Steady-state concentrations require approximately 3-6 months of chronic dosing.
4-6 hours in healthy adults; prolonged to 12-18 hours in severe renal impairment (CrCl <30 mL/min).
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary excretion of metabolites is significant, with approximately 30-40% eliminated in feces. Renal excretion accounts for ~15-20% of total clearance as metabolites.
Renal (80% unchanged) and biliary (15% as metabolites); 5% fecal.
Category C
Category C
Antiarrhythmic
Antiarrhythmic